ThirdWave Obtains FDA Clearance for Proprietary Molecular Test
This is the second time the NASDAQ-traded company Third Wave Technologies has received FDA clearance for its molecular testing products. The companyâ€™s InPlexâ„¢ CF Molecular Test can both detect and identify cystic fibrosis mutations in a patientâ€™s DNA samples. The microfluidic card used for this test was co-developed with the 3M Company. According to the companyâ€™s research of the Cystic Fibrosis Foundation, cystic fibrosis affects more than 30,000 Americans every year, and is the most commonly-inherited disease in the US.